GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rapid Therapeutic Science Laboratories RTSL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Rapid Therapeutic Science Laboratories

Its shares trade under the ticker RTSL. It has been listed since 31 October 2013. In the fiscal year to 31 December 2021, it reported revenue of $534 and a net loss of $4.2m. At that date it held total assets of $2.2m and shareholders' equity of −$1.4m.

Rapid Therapeutic Science Laboratories, Inc operates as an early stage emerging biotech company in the legal hemp and cannabis space. The company is headquartered in De Leon, Texas. The company went IPO on 2013-10-31. The firm is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The firm has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. The company has developed and is continuing to develop a series of complementary products in addition to its inhaler. The company is also focusing on manufacturing its own branded MDI under the nhaler brand name.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
31 Oct 2013
Employees
3

Leadership

Pay as last reported

  • Mr. Donal SchmidtPresident, Chief Executive Officer$105,000
  • Mr. D. Hughes WatlerChief Financial Officer, Director, since 2019$50,025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developed proprietary formula for patent pending cannabinoid compounds in inhaler technology.
  • Operates as an early stage biotech company with 3 full-time employees.
  • Focused on rapid application of therapeutics using inhaler technology.

Weaknesses

  • Limited to 3 full-time employees for all operations.
  • IPO on 31 October 2013 with no further financial details provided.
  • Early stage biotech company with no commercial products yet.

Opportunities

  • Potential commercial opportunities in legal hemp and cannabis space.
  • Development of complementary products alongside the inhaler technology.
  • Manufacturing branded MDI under the nhaler brand name.

Threats

  • Legal hemp and cannabis space subject to regulatory changes.
  • Early stage biotech company facing market competition.
  • No commercial products yet to generate revenue.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.